<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878266</url>
  </required_header>
  <id_info>
    <org_study_id>CCHE-BT002</org_study_id>
    <nct_id>NCT01878266</nct_id>
  </id_info>
  <brief_title>Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children</brief_title>
  <official_title>Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Hospital Egypt 57357</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Cancer Hospital Egypt 57357</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Trial offers a reduction in patient burden, which is especially preferable in children&#xD;
      with a poor compliance and poor performance status. This prospective randomized trial was&#xD;
      extension to the previous controlled prospective study performed in Children's Cancer&#xD;
      Hospital, Egypt and registered at clinicaltrials.com (NCT01635140). The ultimate aim of this&#xD;
      work is to demonstrate noninferiority of the hypofractionated regimens relative to the&#xD;
      conventional regimen in a controlled randomized clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study will add a third arm in which we will increase in the total dose to 4500 cGy in&#xD;
      15 fractions in 3 weeks may lead to improvement in Over-all survival or Progression-Free&#xD;
      Survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median overall-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Pediatric Brain Stem Glioma</condition>
  <arm_group>
    <arm_group_label>Hypofractionated Arm (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated Arm (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Arm (3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Arm (1)</intervention_name>
    <description>A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week</description>
    <arm_group_label>Hypofractionated Arm (1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Arm (2)</intervention_name>
    <description>The total dose to 4500 cGy in 15 fractions in 3 weeks</description>
    <arm_group_label>Hypofractionated Arm (2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Arm (3)</intervention_name>
    <description>A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm</description>
    <arm_group_label>Conventional Arm (3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed patients with a diffuse intrinsic brainstem glioma&#xD;
&#xD;
          2. Aged 2-18years,&#xD;
&#xD;
          3. Have symptoms for less than 3 months and at least two findings of the neurologic&#xD;
             triad: cranial nerve deficits, ataxia, or long tract signs.&#xD;
&#xD;
          4. No performance criteria were required for entry onto the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children were not eligible if they had received any prior therapy other than steroids&#xD;
             Treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Cancer Hospital Egypt 57357</name>
      <address>
        <city>Cairo</city>
        <zip>11441</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse Intrinsic Pontine Glioma (DIPG)</keyword>
  <keyword>Hypofractionated Radiotherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Median survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

